CG Oncology Stock (NASDAQ:CGON)
Previous Close
$40.70
52W Range
$14.80 - $45.56
50D Avg
$40.21
200D Avg
$29.42
Market Cap
$3.10B
Avg Vol (3M)
$999.00K
Beta
1.33
Div Yield
-
CGON Company Profile
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.